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Abstract
Background: The tumor suppressor phosphatase and tensin homolog (PTEN) is a pleiotropic enzyme, inhibiting
phosphatidyl-inositol-3 kinase (PI3K) signaling in the cytosol and stabilizing the genome in the nucleus. Nucleo-cytosolic
partitioning is dependent on the post-translational modifications ubiquitinylation and sumoylation. This cellular
compartmentalization of PTEN was investigated in lung neuroendocrine tumors (lung NET).
Methods: Tumor tissues from 192 lung NET patients (surgical specimens = 183, autopsies = 9) were investigated on tissue
microarrays. PTEN was H-scored by two investigators in nucleus and cytosol using the monoclonal antibody 6H2.1. Results
were correlated with immunoreactivity for USP7 (herpes virus-associated ubiquitin-specific protease 7) and SUMO2/3
(small ubiquitin-related modifier protein 2/3) as well as PTEN and p53 FISH gene status. Clinico-pathologic data
including overall survival, proliferation rate and diagnostic markers (synaptophysin, chromogranin A, Mib-1, TTF-1)
were recorded.
Results: The multicentre cohort included 58 typical carcinoids (TC), 42 atypical carcinoids (AC), 32 large cell
neuroendocrine carcinomas (LCNEC) and 60 small cell lung carcinomas (SCLC). Carcinoids were smaller in size
and had higher synaptophysin and chromogranin A, but lower TTF-1 expressions. Patients with carcinoids were
predominantly female and 10 years younger than patients with LCNEC/SCLC. In comparison to the carcinoids,
LCNEC/SCLC tumors presented a stronger loss of nuclear and cytosolic PTEN associated with a loss of PTEN and
p53. Concomitantly, a loss of nuclear USP7 but increase of nuclear and cytosolic SUMO2/3 was found. Loss of
nuclear and cytosolic PTEN, loss of nuclear USP7 and increase of cytosolic SUMO2/3 thus correlated with poor
survival. Among carcinoids, loss of cytosolic PTEN was predominantly found in TTF1-negative larger tumors of
male patients. Among SCLC, loss of both cytosolic and nuclear PTEN but not proliferation rate or tumor size
delineated a subgroup with poorer survival (all p-values <0.05).
Conclusions: Cellular ubiquitinylation and sumoylation likely influence the functional PTEN loss in high
grade lung NET. Both nuclear and cytosolic PTEN immunoreactivity should be considered for correlation with
clinico-pathologic parameters.
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Background
Lung neuroendocrine tumors (NET) comprise the four
histotypes typical carcinoid (TC), atypical carcinoid (AC),
large cell neuroendocrine carcinoma (LCNEC) and small
cell lung carcinoma (SCLC). In comparison to the carci-
noids, LCNEC and SCLC are aggressive malignancies with
much higher loss of growth control, due to e.g. loss of
tumor suppressors, including protein phosphatase and
tensin homolog (PTEN) [1,2].
The PTEN gene is located on chromosome 10q23.3,
encoding a 403 amino acid residue protein [3]. There is
no alternative protein and cells thus are ultrasensitive to
subtle dosage alterations, referred to as quasi- or hap-
loinsufficiency [4]. PTEN is a protean protein with a
dual-specificity cytosolic lipid and tyrosine phosphatase
activity. Both own phosphorylation status and direct
protein-protein interactions are increasingly investigated
[5]. Recently, a secreted PTEN Long variant was de-
tected [6]. These pleiotropic effects are regulated by
multiple layers of non-genetic regulation, including epi-
genetic silencing and post-transcriptional regulation by
post-translational modifications (PTM) and non-coding
RNAs [7].
Nuclear PTEN was originally detected by immunohis-
tochemistry (IHC) using monoclonal antibody 6H2.1 [8]:
E.g. normal pancreatic islet cells exhibited predomin-
antly nuclear immunoreactivity, whereas endocrine pan-
creatic tumors had a cytosolic expression pattern [9].
This led to the concept that in normal cells PTEN is ra-
ther nuclear, but in neoplastic it is cytosolic. Various
functions were attributed to nuclear PTEN, coining the
term “guardian of the genome” for it. They include pro-
tein association to the centromere-specific binding pro-
tein C (CENP-C) favoring chromosomal stability, to
Rad51/52 favoring DNA double strand break repair, to
p300 favoring high acetylation of p53, to p73 favoring
apoptosis and to the anaphase-promoting complex/
cyclosome (APC/C) favoring cell cycle arrest [10-15].
The protein shuttling between nucleus and cytosol is
dependent on two PTM: Ubiquitinylation and sumoyla-
tion. First, PTEN is ubiquitinylated by NEDD4-1 (neural
precursor cell expressed developmentally downregulated
4–1) as the main E3 ubiquitin ligase. NEDD4-1 is regu-
lated by cofactors NDFIP1 (NEDD4 family-interacting
protein 1) and p34 [16-19]. PTEN mono-ubiquitinylation
resulted in nuclear import, whereas poly-ubiquitinylation
caused proteasome-mediated degradation [20]. USP7 (her-
pes virus-associated ubiquitin-specific protease, HAUSP)
and USP13 are PTEN deubiquitinylases (DUBs) [21-23].
Second, PTEN sumoylated by small ubiquitin-related
modifier proteins (SUMO) is again nuclear. Lysine resi-
dues 254 and 266 as well as the mono-ubiquitinylation site
289 in the C2 domain are SUMO acceptors [24-26] and
PIASxα is a new SUMO E3 ligase [27]. No data exists so
far about PTEN desumoylases but members of the SENP
family are most likely involved [28].
In this study we investigated the compartmentalization
of the PTEN protein in nucleus versus cytosol of lung
NET in a multicenter TMA cohort together with the
USP7 and the SUMO2/3 protein immunoreactivity as
read-outs for cellular ubiquitinylation and sumoylation,
respectively. Results were correlated with the PTEN and
p53 genomic status determined by fluorescence in-situ
hybridization (FISH), with clinico-pathologic data in-
cluding overall survival and with lung NET diagnostic
markers.
Methods
Patients and tissue samples
One hundred and ninety-two patients with surgically
resected (n = 183) or autopsy diagnosed (n = 9) neuroen-
docrine tumours of the lung between 1993 and 2007 at
the University Hospital Zurich (n = 90), the Technical
University of Munich (n = 73) and the Triemli Hospital
Zurich (n = 29) were retrospectively retrieved from the
computer databases and enrolled in this study. The
study was approved by the Institutional Ethical Review
Board of the University Hospital Zurich (reference num-
ber StV 29-2009/14).
Tissue microarray construction
The TMA construction was accomplished with a semi-
automatic tissue arrayer (Beecher Instruments, Sun
Prairie, WI, USA). One or two most representative
tumor areas were chosen and two tissue cores of
0.6 mm diameter assembled into the recipient paraffin
blocks. Additional cores of control tissue, including nor-
mal lung as well as neuroendocrine tumors of the
uterus, the ileo-caecum and the appendix were added.
Four micrometer thick sections were transferred to an
adhesive-coated slide system (Instrumedics, Hackensack,
NJ, USA).
Immunohistochemistry
For PTEN, the automated Leica Bond® IHC platform
(Vision Biosystems, Melbourne, AUS) was used. After
boiling in Tris pH 8 containing buffer H2 for 30 min,
the slide was incubated for 30 min at RT with the mouse
monoclonal anti-PTEN ab clone 6H2.1 (1:200 dilution,
DAKO-Cytomation, Glostrup, DK). Detection was per-
formed using the Refine-DAB Bond kit. For SUMO2/3
and USP7, the Ventana Benchmark® platform (Ventana
Medical Systems, Tucson, AZ, USA) was used. The cell
conditioner 1 standard mono protocol (CC1-mono) was
performed: pre-treatment with boiling for 60 min in
pH 8 Tris buffer following incubation with rabbit poly-
clonal anti-SUMO2/3 ab clone 3742 (1:500 dilution,
Abcam, Cambridge, UK) or rabbit polyclonal anti-USP7
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ab clone TFE1 (1:400 dilution, Bethyl Laboratories, Inc.,
Montgomery, TX, USA) for 60 min at RT. Detection was
done with the UltraMap rabbit DAB kit. For MIB-1,
synaptophysin, chromogranin A and TTF-1 our diagnos-
tic protocols were used.
Nuclear and cytosolic immunoreactivities of PTEN,
SUMO2/3 and USP7 were scored for intensity and fre-
quency. PTEN was independently scored by two investi-
gators (S.C. and A.S.) in a blinded manner. The intensity
was semi-quantitatively scored 0 (negative), 1 (weak), 2
(moderate) or 3 (strong). The percentage of positive cells
was proportionally scored 0 (0%), 10 (1-10%), 50
(11-50%) or 100 (>50%). The H-score was obtained by
multiplication of intensity with percentage (range 0 to
300), summed up for the two cores and divided by two.
Fluorescence in-situ hybridization
For PTEN, a dual colour probe for cytoband 10q23 and
region 10p11.1-q11.1 (Vysis LSI PTEN Spectrum-
Orange and CEP10 Spectrum-Green, Abbott AG, Baar,
CH) was used. For p53, a dual colour probe for cytoband
17p13.1 (172 kb) and region 17p11.1-q11.1 (also Vysis)
was used. For each case, 100 non-overlapping nuclei
were evaluated using an Olympus fluorescence micro-
scope with a 100-fold magnification objective. Tumors
with <100 assessable nuclei were excluded. Normal
PTEN/CEP10 and p53/CEP17 ratios were set at 1.
Statistical analysis
Analyses were computed using the IBM SPSS 22 statistics
software. Correlations of H- or FISH scores with histology or
among each otherwere assessed byKendall’s tau-b tests, using
non-dichotomized data. Inter-observer agreement between S.
C. and A.S. was controlled with Cohen’s kappa coefficient.
Dunnett T3 post-hoc tests were used to assess differences in
ΔH-scoremeans between histotypes two by two. Survival data
was obtained from 156 surgical patients. Patients having an
OS <1month or autopsy cases (n = 9) were excluded. Tumor-
specific survival of carcinoids was not fully assessable.
Markers were dichotomized closest to the median (for all tu-
mors and for SCLC only) and OS analyzed by univariate Cox
regressions and by the Kaplan-Meier method using log rank
tests. A p-value <0.05 was considered significant.
Results
Cohort description
Hundred patients (52%) were men, 92 (48%) women.
The mean age was 57 years (range 15 to 85 years). The
general clinico-pathologic characteristics are summa-
rized in Table 1. Patients with carcinoids were 10 years
younger and preferentially female. In the smaller carci-
noids, expression of the neuroendocrine markers synap-
tophysin and chromogranin A was higher, but of TTF1
lower in comparison to LCNEC/SCLC. Carcinoids (TC
vs. AC) were separable by the proliferation index Mib-1
and the tumor size.
PTEN immunoreactivity in nucleus versus cytosol and
FISH
The monoclonal anti-PTEN antibody clone 6H2.1 was
tested on an endometrial carcinoma TMA as well as on
a multi-tumor tissue and cell line microarray and was
found to produce distinct nuclear and cytosolic immu-
noreactivity. All types of lung NET exhibited nuclear
and cytosolic staining. The same was observed for
SUMO2/3 but for USP7 only the nuclear signal could be
scored. A minor frequency of PTEN deletion was found
with a mean of 0.93 for the PTEN/CEP10 ratio (range
14–118). The p53 deletion was more pronounced with a
mean of 0.84 for the p53/CEP17 ratio (range 50–123).
Table 1 Summary of clinical data including age, sex and tumor size (Tu size) as well as relevant diagnostic
immunohistochemistry markers for lung NET, including proliferation index (Mib-1), neuroendocrine (Synapto, Chrom
A) and lung differentiation (TTF1)
Age Sex Tu size Mib 1 Synapto ChromA TTF1
n mean m/f mean(cm) mean(%) any pos. any pos. any pos.
TC 58 53 23/35 2.2 1.6 98% 98% 45%
AC 42 49 14/28 2.8 3.1 100% 98% 48%
LCNEC 32 64 22/10 3.5 57 91% 63% 94%
SCLC 60 62 41/19 3.3 51 93% 50% 80%
All 4 histotypes p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
tau 0.208 −0.245 0.222 0.564 −0.416 −0.634 0.379
Low vs. high grade p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
tau 0.291 −0.315 0.215 0.647 −0.527 −0.723 0.467
LCNEC vs. SCLC p n.s. n.s. n.s. n.s. n.s. n.s. n.s.
tau
Correlation with categorized 4 histotypes, only low vs. high grade, only TC vs. AC and only LCNEC vs. SCLC. p = p-value, tau = correlation coefficient, n.s. = not significant.
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Representative IHC and FISH examples are presented in
Figures 1 and 2.
Correlation of PTEN immunoreactivity with lung NET
histology
The H-score means for nuclear and cytosolic PTEN pro-
tein, correlated with histology are shown in Table 2. Robust
expression was observed with a maximal H-score of 260
(range 0 to 300) in AC. Good inter-observer agreement
was found with kappa values for nuclear and cytosolic H-
scores of 0.710 and 0.791 for core 1, 0.684 and 0.731 for
core 2, respectively. Cytosolic was always higher than
nuclear PTEN expression in all histologic types. A pro-
nounced protein loss in both compartments was observed
in high grade lung NET. Differentiation among carcinoids
was not possible. However, for observer S.C. a discrepancy
between LCNEC and SCLC was found: SCLC showed a
predominant loss of nuclear PTEN whereas in LCNEC it
was predominantly cytosolic. A Dunnett T3 post hoc test
showed a difference of ΔH score means between SCLC
and any other histology (p < 0.001).
Correlation of other markers with histology
In the high grade tumors, a decrease of nuclear USP7 as
well as of the PTEN/CEP10 and p53/CEP17 ratios was
found. In contrast, the expression of SUMO2/3 in-
creased in nucleus and cytosol. Apart from p53 deletion
in TC vs. AC and nuclear or cytosolic PTEN S.C., a dis-
tinction among the low or the high grade tumors was
not possible (Table 2).
A. Lung B. TC
C. LCNEC D. TC
F. TCE. SCLC
Figure 1 Representative H-scores in nucleus (nucl) and cytosol (cyto) for PTEN immunoreactivity using Mab clone 6H2.1. Original
magnifications are 200-400x, except insert F (12.5x). A. Normal lung alveolar pneumocytes type. B. TC with PTEN score nucl 0 and cyto 0. C.
LCNEC with nucl 0 and cyto 3x100. Necrotic cells on the left side were not counted. D. TC with nucl 3x100 and cyto 1x100. E. SCLC with nucl 0
and cyto 3x100. F. TC with nucl 3x100 and cyto 3x100. Insert: Whole section of lung TC showing homogenous PTEN staining across the tumor
surface. Holes represent areas of removed tissue punches.
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A. TC B. SCLC
C. LCNEC D. AC
E. Normal F. Deletion
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T
E
N
G. All Histology H. SCLC
PTEN cyto S.C. low
n=27, event=25
PTEN cyto S.C. high 
n=24, event=17
LCNEC
SCLC
TC
AC
p=0.010p<0.001
Figure 2 Representative H-scores for SUMO2/3 and USP7, PTEN FISH examples and Kaplan-Meier curves. A. TC with SUMO2/3 nucl 0 and
cyto 0. B. SCLC with SUMO2/3 nucl 3x50 and cyto 2x100. C. LCNEC with USP7 nucl 1x50. D. AC with USP7 nucl 3x100. E. TC with normal PTEN
status. F. SCLC with PTEN deletion. Original magnifications 200x for IHC and 630x for FISH. G. OS for all lung NET. H. OS for dichotomized
cytosolic PTEN S.C. among SCLC.
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Correlation of PTEN immunoreactivity with other markers
and with clinico-pathologic data for carcinoids
Irrespective of histology, loss of nuclear and cytosolic
PTEN correlated with concomitant loss of USP7, PTEN
and p53. Correlations of PTEN protein with SUMO2/3
were not significant or inverse (for nuclear PTEN and
cytosolic SUMO2/3). However, among SCLC nuclear
and cytosolic PTEN was positively correlated with cyto-
solic SUMO2/3 (all p-values <0.05, correlation coeffi-
cients not shown). PTEN protein was further computed
against the relevant clinico-pathologic data of carcinoids
in order to test for a potential subgroup (Table 3). For
both investigators, a cytosolic but not nuclear loss of
PTEN correlated with TTF-1 negative larger tumors of
male patients.
Correlation of markers with overall survival
The median OS for the total cohort was 106 months
(range 1 to 169 months, SE = 17.8 months). Five-year OS
was 59%, for TC 97%, for AC 93.5%, for LCNEC 24%
and for SCLC 22.4%. Table 4 shows the univariate Cox
regression survival analyses. All markers were significant
apart from TTF-1 and nuclear SUMO2/3, whereby hist-
ology showed the highest hazard ratio. As seen in
Figure 2, survival for TC and AC was similar 5 to 6 years
after surgery. Thereafter, AC showed a worse survival
compared to TC. It is worth mentioning that the repre-
sented curves are from overall and not tumor-specific
survivals. Indeed, data for tumor-specific survival was
not fully assessable. The number of LCNEC with avail-
able survival (n = 21) was considered too low to compute
any additional statistics. We performed a subgroup
analysis among SCLC (n = 51). High expression of
synaptophysin, TTF-1, cytosolic PTEN and nuclear as
well cytosolic SUMO2/3 were all protective in terms of
survival. Thus, loss of these markers but not increased
tumor size or higher proliferation rate Mib-1 defined a
subgroup of SCLC with particularly poor prognosis. In
the multivariate analysis, dichotomized PTEN immuno-
reactivity was finally challenged against categorized hist-
ology, using TC as reference. High cytosolic but not
nuclear PTEN for scorer S.C. remained significant
(p-value = 0.001, HR 0.27, 95% CI 0.14-0.58), whereas
Table 2 Summary of mean values for PTEN S.C./A.S., USP7 and SUMO2/3 protein H-score as well as PTEN and p35 FISH
ratios (R) among the different neuroendocrine histotypes
PTEN S.C. PTEN A.S. USP7 SUMO2/3 PTEN p53
Nucl Cyto Nucl Cyto Nucl Nucl Cyto FISH FISH
n mean H mean H mean H mean H mean H mean H mean H mean R mean R
TC 58 218 234 168 248 226 84 72 0.96 0.90
AC 42 215 237 171 260 234 91 64 0.96 0.84
LCNEC 32 86 114 56 104 178 171 139 0.90 0.81
SCLC 60 49 163 42 146 145 152 137 0.90 0.79
All 4 histotypes p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
tau −0.556 −0.314 −0.464 −0.392 −0.324 0.297 0.272 −0.149 −0.333
Low vs. high grade p <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
tau −0.621 −0.429 −0.540 −0.520 −0.371 0.370 0.350 −0.206 −0.307
TC vs. AC p n.s. n.s. n.s. n.s. n.s. n.s. n.s. n.s. <0.001
tau −0.280
LCNEC vs. SCLC p 0.006 0.003 n.s. n.s. n.s. n.s. n.s. n.s. n.s.
tau −0.244 0.243
Correlation with categorized 4 histotypes, only low vs. high grade, only TC vs. AC and only LCNEC vs. SCLC. p = p-value, tau = correlation coefficient, n.s. = not significant.
Table 3 Correlation of PTEN protein expression in nucleus
and cytosol with the clinico-pathologic data for
carcinoids
PTEN S.C. PTEN A.S.
Carcinoids Nucl Cyto Nucl Cyto
Age p n.s. n.s. n.s. n.s.
tau
Sex(m/f) p n.s. 0.012 n.s. 0.002
tau 0.222 0.291
Tumor size p 0.006 0.001 n.s. <0.001
tau −0.197 −0.236 −0.322
Mib-1 p n.s. n.s. n.s. n.s.
tau
Synaptophysin p 0.003 0.003 n.s. n.s.
tau 0.301 0.317
Chromogranin A p n.s. n.s. n.s. n.s.
tau
TTF-1 p n.s. 0.003 n.s. 0.008
tau 0.255 0.222
p = p-value, tau = correlation coefficient, n.s. = not significant.
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the transition from TC to AC turned out not to be sig-
nificant. These results favor a general protective effect of
PTEN, independent of histology.
PTEN function in nucleus and cytosol
A literature review was performed on all Pubmed ab-
stracts (2011–2014) using the term “PTEN”. Relevant
data on post-translational modifications and nucleo-
cytosolic partitioning is summarized in Figure 3.
Discussion
In this study, we show that PTEN protein is expressed
in both nucleus and cytosol of lung NET. In comparison
to carcinoids, LCNEC/SCLC presented a protein loss in
both compartments concomitant with loss of the PTEN
and p53 genes. The PTEN loss correlated with a loss of
nuclear USP7. In contrast, high grade lung NET pre-
sented an increase of sumoylation.
There is a lack of standardization for a best practice
PTEN IHC protocol and nuclear immunoreactivity as
reported in endocrine pancreatic tumors and thyroid
[29,30] was originally considered an artefact. In 2005,
Pallares et al. tested 4 different clones on endometrial
carcinomas, including a polyclonal and the monoclonals
28H6, 10P03 and 6H2.1. 6H2.1 was the only one to
show a correlation between immunoreactivity and PTEN
gene alterations such as mutation, deletion or promoter
methylation [8]. This is corroborated by 2 new studies in
prostate and renal cell as well as endometrial carcinoma
[31,32] which propose 6H2.1 as the antibody of choice,
demonstrating excellent sensitivity for both nuclear and
cytoplasmic staining, specificity for PTEN immunoblot
and good correlation with PTEN FISH status with re-
gard to nuclear staining. Moreover, a recent follow-up to
the Pallares study by Maiques et al. analysed the relevant
analytical and preanalytical variables for PTEN IHC
using 6H2.1 and DAKO-based reagents [33].
PTEN expression in normal cells such as alveolar wall
pneumocytes or stromal fibroblasts is predominantly nu-
clear (Figure 1A), corroborating the concept that in
non-neoplastic cells, the protein fulfils rather nuclear
functions. Taking together the scores of 2 observers, the
H-score presented a five-fold range (maximum 248 in
TC, PTEN cytosol A.S. and minimum 49 in SCLC,
PTEN nuclear S.C.). For a haplo-insufficient protein, this
may fit well with the different behaviour of a TC versus
a SCLC.
The PTEN protein loss correlated with a nuclear USP7
loss, indicating a reduction of de-ubiquitinylation, thus an
increase of poly-ubiquitinylated enzyme targeted for pro-
teasome degradation. USP7 also removes ubiquitin from
p53 and the p53 E3 ubiquitin ligase MDM2 [34], therefore
is a functional dose regulator of two important tumor sup-
pressors. The regulation of USP7 in tumor cell prolifera-
tion seems to be organ-specific. In prostate carcinoma,
both USP7 and MDM4 overexpression were associated
with tumor aggressiveness, while both up- and down-
regulation was found to inhibit colon carcinoma cell pro-
liferation due to enhanced degradation of MDM2 follow-
ing constitutively elevated p53 levels [21,35,36].
In contrast to PTEN and USP7, the expression of
SUMO2/3 globally increased in the high grade tumors.
These results may be explained by a concept of differen-
tial sumoylation among lung NET and/or a potential se-
questration mechanism. Sequestration of nuclear PTEN
was described for protein phosphatase-1 nuclear targeting
subunit (PNUTS, PPP1R10) [37]. Another model indi-
cated conformationally-dependent cytoplasmic retention
and negative regulation of nuclear PTEN activity by onco-
genic cytoplasmic p27Kip1 [38,39].
Both PTEN and p53 are sumoylated proteins that can
be identified in SUMO-traps using SUMO interacting
motifs (SIMs) [40]. PTEN undergoes complex interac-
tions in the nucleus with p53, stimulating p300-
mediated p53 acetylation following tetramerization [10]
as well as with the p53 family member p73 [13]. In-
versely, p53 can up- or downregulate PTEN, e.g. via
caspase-mediated degradation [41,42]. p53 itself is ubi-
quitinylated by MDM2 [43,44]. It remains to be seen
how ubiquitinylation and/or sumoylation affect PTEN-
p53 interaction. There is also crosstalk between sumoy-
lation and ubiquitinylation: E.g. the SUMO E3 ligase
Table 4 Summary of univariate Cox regression survival
analyses for all tumors and only SCLC
All tumors (n = 156) SCLC (n = 51)
p HR p HR
Histology <0.001 10.81
Age 0.010 1.85 n.s.
Sex 0.001 0.44 n.s.
Tumor size 0.002 2.28 n.s.
Mib-1 <0.001 6.39 n.s.
Synaptophysin <0.001 0.27 0.042 0.52
Chromogranin A <0.001 0.13 n.s.
TTF-1 n.s. 0.006 0.42
PTEN Nucl S.C. <0.001 0.21 n.s.
PTEN Nucl A.S. <0.001 0.36 n.s.
PTEN Cyto S.C. <0.001 0.15 0.010 0.42
PTEN Cyto A.S. <0.001 0.17 0.025 0.49
SUMO2/3 Nucl n.s. 0.004 0.39
SUMO2/3 Cyto 0.006 1.97 0.032 0.51
USP7 Nucl <0.001 0.27 n.s.
PTEN FISH 0.006 0.44 n.s.
p53 FISH 0.024 0.57 n.s.
HR = hazard ratio, p = p-value, n.s. = not significant.
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PIASxα enhanced PTEN protein stability by reducing its
ubiquitinylation [27] and PTEN-SUMO1 showed a re-
duced capacity to form covalent interactions with mono-
ubiquitin [25].
How the post-translationally modified PTEN protein,
including PTEN-SUMO, −Ub and potentially -Ac, −P or
-OC (open conformation)-p27 shuttles between nucleus
and cytosol is unclear [45,46]. The protein lacks a true
nuclear localization signal. Different mechanisms were
proposed for this shuttling including simple diffusion
through nuclear pores [47], active RAN-mediated
nuclear import [48] and transport via the major vault
protein (MVP) [49].
The histopathologic diagnosis between TC and AC is
notoriously difficult to be made. Indeed, there is a trend
to pool them into carcinoids and secondarily stratify
them according to molecular data. This view is corrobo-
rated by the similar survivals curves on Figure 2. In our
opinion, the entity “atypical carcinoid” may simply arise
by the fact that enlarging carcinoids have a higher mi-
totic rate and more necrotic foci. These data need how-
ever to be interpreted with caution, since OS and not
Figure 3 Schematic depiction of PTEN functions in nucleus and cytosol with regard to its posttranslational modifications. The classic
pathway takes place in the cytosol underneath the plasma membrane whereby the phosphatase activity decreases the level of PIP3. The
inhibition of Akt/PKB results in decreased cell proliferation and increased apoptosis. Further, a decrease of the nuclear E3 ubiquitin ligase MDM2
acting on p53 is observed. Nuclear PTEN forms a complex genome protection network by activation of Rad51/52 (DNA double strand repair),
binding to CENP-C (chromosomal stability) and APC/C (slowdown of the cell cycle). It undergoes complex interactions with p53 family members.
PTEN and p53 act on each other affecting acetylation and transcription. As net effect, p21, p27 and maspin are upregulated, acting as tumor
suppressors in this context. PTEN sumoylation is achieved by the E3 SUMO ligase PIASxα, desumoylation most likely by a member of the SENP
family. PIASxα crosstalks with the ubiquitinylation pathway. NEDD4-1 is the main E3 ubiquitin ligase regulated by cofactors p34 and NDFIP1.
De-ubiquitinylation is achieved by USP7 or USP13. Poly-ubiquitinylated PTEN, p53 and MDM2 proteins are targeted for proteasome mediated
degradation. Both PTEN and p53 may also be acetylated and phosphorylated to a substantial degree in the nucleus. The PTEN Long variant is
secreted into the extracellular space. Cytosolic p27 is oncogenic in contrast to the nuclear moiety by e.g. retention of open conformation PTEN
(PTEN-OC) in the cytoplasm targeted for proteasome degradation.
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tumor-specific survival was computed. This is of signifi-
cant importance for mainly indolent tumors such as car-
cinoids. For this same reason, we did not perform a
subgroup analysis among carcinoids. However, the cor-
relation with the other clinico-pathologic parameters
showed that a PTEN loss is primarily found in male with
TTF-1 negative larger carcinoids.
Differences between LCNEC and SCLC are also de-
bated. SCLC cells have a size less than the diameter of 3
small resting lymphocytes, but interspersed larger ele-
ments are often observed. All markers apart nuclear and
cytosolic PTEN of scorer S.C. failed to distinguish them
and no survival differences were found. The survival re-
sults favour a concept of single high-grade lung NET
[50]. Among SCLC, we identified a subset in which high
cytosolic PTEN, high nuclear and cytosolic SUMO2/3,
high synaptophysin and high TTF1 were associated with
better survival. As observed in the carcinoids as well,
these results are best interpreted as tumor dedifferenti-
ation being associated with loss of respective tumor sup-
pressor and differentiation markers.
From a therapeutic point of view, loss of PTEN leaves
cells sensitive to DNA damage, but it also provides a
PI3K pathway survival signal, the inhibition of which
could kill the tumor [51]. This concept has created con-
siderable oncologic interest since numerous PI3K inhibi-
tors are currently investigated and may be combined
with DNA damaging agents. It is conceivable that PTEN
PTM interfere with PI3K inhibition via determination of
the cytosolic enzyme activity. A further question is to
what degree such PTM would affect the ratio between
intracellular PTEN and its secreted variant PTEN Long
that may be bestowed to cancer cells from stroma or in-
troduced biopharmaceutical.
Conclusion
In summary, cellular ubiquitinylation and sumoylation
likely influence the functional PTEN loss in high grade
lung NET. Both nuclear and cytosolic PTEN immunoreac-
tivity should be considered for correlation with clinico-
pathologic parameters.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SC and AS participated in designing the study, collecting data, TMA scoring,
computing statistical analysis and writing of the manuscript. VT participated
in collecting data, TMA scoring and manuscript writing. AA participated in
TMA preparation and scoring as well as data collection. TW participated in
study design, TMA scoring and manuscript writing. PK and CO participated
in TMA preparation and data collection. WW participated in study design
and manuscript revision. All authors read and approved the final manuscript.
Acknowledgements
We would like to thank Martina Storz, Silvia Behnke, Jasmine Roth and Doris
Kradolfer for excellent technical assistance with construction of the TMA, IHC
and FISH, respectively. Prof. B. Seifert and Dr. M. Roos, Institute of Social and
Preventive Medicine, Biostatistics Unit, Hirschengraben 84, CH-8001 Zurich
are kindly acknowledged for statistical advisory. Prof. H. Moch and Prof. A.
Perren are acknowledged for critical reading of the manuscript. “Lungenliga
Zürich” supported S.C. and W.W. for this work, while the Center for Clinical
Research, University Hospital and University of Zurich supported A.S. (ref. nr.
DFL1225).
Author details
1Division of Thoracic Surgery, University Hospital, Zurich, Switzerland.
2Institute of Surgical Pathology, University Hospital Zurich,
Schmelzbergstrasse 12, CH-8091 Zurich, Switzerland. 3Institute of Pathology,
Triemli Hospital, Zurich, Switzerland. 4Institute of Pathology, Cantonal
Hospital, St. Gallen, Switzerland.
Received: 13 October 2014 Accepted: 12 February 2015
References
1. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, et al. Loss of p130
accelerates tumor development in a mouse model for human small-cell
lung carcinoma. Cancer Res. 2010;70(10):3877–83.
2. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al.
Integrative genome analyses identify key somatic driver mutations of
small-cell lung cancer. Nat Genet. 2012;44(10):1104–10.
3. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative
protein tyrosine phosphatase gene mutated in human brain, breast, and
prostate cancer. Science. 1997;275(5308):1943–7.
4. Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, et al.
Subtle variations in Pten dose determine cancer susceptibility. Nat Genet.
2010;42(5):454–8.
5. Shi Y, Paluch BE, Wang X, Jiang X. PTEN at a glance. J Cell Sci. 2012;125
(Pt 20):4687–92.
6. Hopkins BD, Fine B, Steinbach N, Dendy M, Rapp Z, Shaw J, et al. A secreted
PTEN phosphatase that enters cells to alter signaling and survival. Science.
2013;341(6144):399–402.
7. Correia NC, Girio A, Antunes I, Martins LR, Barata JT. The multiple layers of
non-genetic regulation of PTEN tumour suppressor activity. Eur J Cancer.
2014;50(1):216–25.
8. Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, Rue M, et al.
Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue
microarray study with a comparison of four commercial antibodies in
correlation with molecular abnormalities. Mod Pathol. 2005;18(5):719–27.
9. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, et al.
Mutation and expression analyses reveal differential subcellular
compartmentalization of PTEN in endocrine pancreatic tumors compared to
normal islet cells. Am J Pathol. 2000;157(4):1097–103.
10. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into
maintenance of high p53 acetylation by PTEN. Mol Cell. 2006;23(4):575–87.
11. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. Essential role
for nuclear PTEN in maintaining chromosomal integrity. Cell. 2007;128
(1):157–70.
12. Choi BH, Chen Y, Dai W. Chromatin PTEN is involved in DNA damage
response partly through regulating Rad52 sumoylation. Cell Cycle.
2013;12(21):3442–7.
13. Lehman JA, Waning DL, Batuello CN, Cipriano R, Kadakia MP, Mayo LD.
Induction of apoptotic genes by a p73-phosphatase and tensin homolog
(p73-PTEN) protein complex in response to genotoxic stress. J Biol Chem.
2011;286(42):36631–40.
14. Song MS, Carracedo A, Salmena L, Song SJ, Egia A, Malumbres M, et al.
Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a
phosphatase-independent manner. Cell. 2011;144(2):187–99.
15. Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN
tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–96.
16. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, Gao Z, et al. NEDD4-1 is
a proto-oncogenic ubiquitin ligase for PTEN. Cell. 2007;128(1):129–39.
17. Howitt J, Lackovic J, Low LH, Naguib A, Macintyre A, Goh CP, et al. Ndfip1
regulates nuclear Pten import in vivo to promote neuronal survival
following cerebral ischemia. J Cell Biol. 2012;196(1):29–36.
18. Jung S, Li C, Jeong D, Lee S, Ohk J, Park M, et al. Oncogenic function of
p34SEI-1 via NEDD41mediated PTEN ubiquitination/degradation and
activation of the PI3K/AKT pathway. Int J Oncol. 2013;43(5):1587–95.
Collaud et al. BMC Cancer  (2015) 15:74 Page 9 of 10
19. Hong SW, Moon JH, Kim JS, Shin JS, Jung KA, Lee WK, et al. p34 is a novel
regulator of the oncogenic behavior of NEDD4-1 and PTEN. Cell Death
Differ. 2014;21(1):146–60.
20. Trotman LC, Wang X, Alimonti A, Chen Z, Teruya-Feldstein J, Yang H, et al.
Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell.
2007;128(1):141–56.
21. Song MS, Salmena L, Carracedo A, Egia A, Lo-Coco F, Teruya-Feldstein J,
et al. The deubiquitinylation and localization of PTEN are regulated by a
HAUSP-PML network. Nature. 2008;455(7214):813–7.
22. Faesen AC, Dirac AM, Shanmugham A, Ovaa H, Perrakis A, Sixma TK.
Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like
domain and allosteric regulation by GMP-synthetase. Mol Cell.
2011;44(1):147–59.
23. Zhang J, Zhang P, Wei Y, Piao HL, Wang W, Maddika S, et al. Deubiquitylation
and stabilization of PTEN by USP13. Nat Cell Biol. 2013;15(12):1486–94.
24. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, et al. SUMO1 modification of
PTEN regulates tumorigenesis by controlling its association with the plasma
membrane. Nat Commun. 2012;3:911.
25. Gonzalez-Santamaria J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la
Cruz-Herrera CF, Gonzalez D, et al. Regulation of the tumor suppressor PTEN
by SUMO. Cell Death Dis. 2012;3:e393.
26. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, et al. Nuclear PTEN
controls DNA repair and sensitivity to genotoxic stress. Science. 2013;341
(6144):395–9.
27. Wang W, Chen Y, Wang S, Hu N, Cao Z, Tong T, et al. PIASxalpha enhances
SUMO1 modification of PTEN as a SUMO E3 ligase. J Biol Chem.
2014;289(6):3217–30.
28. Hickey CM, Wilson NR, Hochstrasser M. Function and regulation of SUMO
proteases. Nat Rev Mol Cell Biol. 2012;13(12):755–66.
29. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U, et al. Differential
nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and
benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156
(5):1693–700.
30. Perren A, Weng LP, Boag AH, Ziebold U, Thakore K, Dahia PL, et al.
Immunohistochemical evidence of loss of PTEN expression in primary
ductal adenocarcinomas of the breast. Am J Pathol. 1999;155(4):1253–60.
31. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B.
Pathologic scoring of PTEN immunohistochemistry in endometrial
carcinoma is highly reproducible. Int J Gynecol Pathol. 2012;31(1):48–56.
32. Carvalho KC, Maia BM, Omae SV, Rocha AA, Covizzi LP, Vassallo J, et al. Best
practice for PTEN gene and protein assessment in anatomic pathology. Acta
Histochem. 2014;116(1):25–31.
33. Maiques O, Santacana M, Valls J, Pallares J, Mirantes C, Gatius S, et al.
Optimal protocol for PTEN immunostaining; role of analytical and
preanalytical variables in PTEN staining in normal and neoplastic
endometrial, breast, and prostatic tissues. Hum Pathol. 2014;45(3):522–32.
34. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C, Vogelstein B.
Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature.
2004;428(6982):1. p following 486.
35. Becker K, Marchenko ND, Palacios G, Moll UM. A role of HAUSP in tumor
suppression in a human colon carcinoma xenograft model. Cell Cycle.
2008;7(9):1205–13.
36. Sun T, Lee GS, Oh WK, Pomerantz M, Yang M, Xie W, et al. Single-nucleotide
polymorphisms in p53 pathway and aggressiveness of prostate cancer in a
Caucasian population. Clin Cancer Res. 2010;16(21):5244–51.
37. Kavela S, Shinde SR, Ratheesh R, Viswakalyan K, Bashyam MD, Gowrishankar
S, et al. PNUTS functions as a proto-oncogene by sequestering PTEN. Cancer
Res. 2013;73(1):205–14.
38. Andres-Pons A, Gil A, Oliver MD, Sotelo NS, Pulido R. Cytoplasmic p27Kip1
counteracts the pro-apoptotic function of the open conformation of PTEN
by retention and destabilization of PTEN outside of the nucleus. Cell Signal.
2012;24(2):577–87.
39. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and
tensin homologue deleted on chromosome 10 (PTEN) differentially
regulates the cell cycle and apoptosis. Cancer Res. 2005;65(18):8096–100.
40. Da Silva-Ferrada E, Xolalpa W, Lang V, Aillet F, Martin-Ruiz I, de la Cruz-
Herrera CF, et al. Analysis of SUMOylated proteins using SUMO-traps.
Sci Rep. 2013;3:1690.
41. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, et al. Regulation
of PTEN transcription by p53. Mol Cell. 2001;8(2):317–25.
42. Tang Y, Eng C. p53 down-regulates phosphatase and tensin homologue
deleted on chromosome 10 protein stability partially through caspase-
mediated degradation in cells with proteasome dysfunction. Cancer Res.
2006;66(12):6139–48.
43. Mayo LD, Donner DB. A phosphatidylinositol 3-kinase/Akt pathway
promotes translocation of Mdm2 from the cytoplasm to the nucleus.
Proc Natl Acad Sci U S A. 2001;98(20):11598–603.
44. Chu EC, Tarnawski AS. PTEN regulatory functions in tumor suppression and
cell biology. Med Sci Monit. 2004;10(10):RA235–241.
45. Kau TR, Way JC, Silver PA. Nuclear transport and cancer: from mechanism to
intervention. Nat Rev Cancer. 2004;4(2):106–17.
46. Fata JE, Debnath S, Jenkins Jr EC, Fournier MV. Nongenomic Mechanisms of
PTEN Regulation. International journal of cell biology. 2012;2012:379685.
47. Liu F, Wagner S, Campbell RB, Nickerson JA, Schiffer CA, Ross AH. PTEN
enters the nucleus by diffusion. J Cell Biochem. 2005;96(2):221–34.
48. Gil A, Andres-Pons A, Fernandez E, Valiente M, Torres J, Cervera J, et al.
Nuclear localization of PTEN by a Ran-dependent mechanism enhances
apoptosis: Involvement of an N-terminal nuclear localization domain and
multiple nuclear exclusion motifs. Mol Biol Cell. 2006;17(9):4002–13.
49. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA. Vaults: a
ribonucleoprotein particle involved in drug resistance? Oncogene. 2003;22
(47):7458–67.
50. Jones MH, Virtanen C, Honjoh D, Miyoshi T, Satoh Y, Okumura S, et al. Two
prognostically significant subtypes of high-grade lung neuroendocrine tu-
mours independent of small-cell and large-cell neuroendocrine carcinomas
identified by gene expression profiles. Lancet. 2004;363(9411):775–81.
51. Leslie NR, Brunton VG. Cell biology. Where is PTEN? Science. 2013;341
(6144):355–6.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Collaud et al. BMC Cancer  (2015) 15:74 Page 10 of 10
